Abstract The degree of adherence to oral anticancer agents may influence treatment efficacy. Tamoxifen and toremifene usage data from two International Breast Cancer Study Group (IBCSG) studies were used to evaluate the impact of treatment adherence on the efficacy of these two selective estrogen receptor modulators (SERMs). Between 1993 and 1999, IBCSG Trial 13-93 randomized premenopausal women with node-positive disease to tamoxifen or no endocrine therapy and IBCSG Trial 14-93 compared tamoxifen and toremifene in postmenopausal women with node-positive disease. 690 women with estrogen-receptor positive enrolled in these two trials were alive and diseasefree 4 years after the start of SERM. The median follow up for this analysis was 9.0 years. Using a Kaplan-Meier landmark analysis at 4 years, the 609 women completing at least 4 years of SERM had improved 10-year disease-free survival (DFS) (71 %) compared with the 81 women taking less than 4 years (64 %), but these differences did not reach statistical significance [DFS hazard ratio (\4 year/ 4? year) 1.31, 95 % CI 0.86-1.98), p value = 0.20]. Women who completed less than 4 years of SERM treatment (12 %) appeared not to have achieved the full benefit from their therapy. These results suggest that more effort should be made to educate women regarding the benefits of a full course of treatment. This is especially important in light of the results of the recently reported ATLAS and aTTom trials which suggest a benefit of 10 years of tamoxifen.
Introduction
Adherence to long-term oral cancer therapy can have a major impact on treatment efficacy [1] [2] [3] , especially if unrecognised by healthcare providers. Adherence is defined as ''the degree or extent of conformity to the recommendations about day-to-day treatment with respect to the timing, dosage, and frequency'' [4] and is routinely used as synonymous with compliance, which can be associated too closely with blame. Another synonym for adherence is medication persistence, i.e., treatment continuation for the prescribed duration.
There currently is no consensus, and limited data are available on the threshold for ''adequate adherence'' [5] , with 80 % being considered an acceptable cutoff [2] . Adherence to long-lasting therapy for chronic illnesses in developed countries is on average 50 %, but these reports do not usually include anticancer treatments [6, 7] . Patient adherence to oral anticancer treatment is variable and difficult to predict [8, 9] .
Patient-related, therapy-related, or healthcare systemassociated factors may affect adherence. Age has been identified as one of the patient-related key factors linked with lower adherence [2, 10] : older age ([75 years) [11] [12] [13] [14] [15] and younger age (\45 years) [2, 10, [16] [17] [18] are both significantly associated with poor adherence. In particular with regard to endocrine therapy for early breast cancer, most data for the general population are based on either self-reporting by patients, with the relative potential biases, or insurance/pharmacy databases recording medication refills [9] : overall, adherence to adjuvant tamoxifen ranges from 25 to 96 % [2, 10, 14, 19] . Noncompliance to aromatase inhibitors (AIs) has been documented in patients treated outside clinical trials [16, 17, 20, 21] . In the largest series report, during the first year, between 12 and 23 % of women were nonadherent [22, 23] , with mean adherence significantly decreasing with time [22] .
The risk of reduced efficacy as a consequence of nonadherence is difficult to address. The relatively long halflife of tamoxifen (7-14-day) [23] may not translate into reduced efficacy from occasionally missing tablets, while AIs have a much shorter half-life (approximately 2 days for letrozole and anastrozole and only 27 h for exemestane) [24] with a greater potential detrimental effect on outcome from sporadic nonadherence.
Adherence of less than 80 % (determined by prescription records) was associated with poorer survival at 2.4 years (HR 1.10, 95 % CI 0.001-1.21), measured as allcause mortality, in a series of 1,633 Irish women under tamoxifen [4] . This observation was recently confirmed in a second series of 8,769 women from northern California, using either tamoxifen or AIs [25] : adjusting for clinical and demographic variables, at median follow up of 4.4 years, both early discontinuation (HR 1.26, 95 % CI 1.09-1.46) and nonadherence (HR 1.49, 95 % CI 1.23-1.81) (measured by automated pharmacy records and prescription refill rates) among those who continued, were independent predictors of all-cause mortality.
When patients participating in clinical trials are nonadherent, inaccurate, and flawed conclusions may result, possibly affecting therapeutic recommendations for the general population. Few data from randomized controlled trials are available [26] . The NCIC MA.17 trial (extended adjuvant letrozole after 5 years of tamoxifen) reported reasons for discontinuation: patient refusal (11.4 % letrozole; 11.1 % placebo), toxicity (4.9 % letrozole; 3.6 % placebo), and ''other reasons'' (3.8 % letrozole; 4.7 %, placebo) [27] . The NSABP B-14 trial (tamoxifen for up to 10 years) interestingly showed, in the first 5 years, therapy discontinuation was more frequent with placebo (13.0 %) than tamoxifen (10.2 %), suggesting that medication-related adverse events are not necessarily a reason for discontinuation [28] . A meta-analysis of clinical studies [2] evaluating persistence with tamoxifen or an AI, reported that overall, 23 to 28 % of patients followed for at least 4 years discontinued their oral endocrine therapy earlier than recommended. In the ATLAS trial, 2 years after entry, 84 % of patients allocated to continue were still on tamoxifen compared with 4 % of controls, a difference of 80 % [31] .
Patients and methods
Between 1993 and 1999 the International Breast Cancer Study Group (IBCSG) conducted two complementary randomized adjuvant trials for pre-and postmenopausal patients with node-positive breast cancer evaluating the efficacy of a chemotherapy treatment gap and also addressing an endocrine therapy question (IBCSG trials 13-93 and 14-93). Trial 13-93 enrolled 1,246 premenopausal women and studied the role of tamoxifen. Trial 14-93 accrued 969 postmenopausal patients and compared the efficacy of two selective estrogen receptor modulators (SERMs), tamoxifen and toremifene. Following their cytotoxic treatment, 364 women in Trial 13-93 were randomized to receive tamoxifen, and 393 women in Trial 14-93 were randomized to receive toremifene (N = 199) or tamoxifen (N = 194). In addition, 199 women in Trial 14-93 were directly assigned to receive tamoxifen, due to the unavailability of toremifene in some countries. At median follow-up of 7 years, the results of Trial 13-93 indicated that tamoxifen after adjuvant chemotherapy versus no tamoxifen significantly improved disease-free survival (DFS) in premenopausal patients with estrogenreceptor positive (ER?) disease (HR 0.59, 95 % CI 0.46-0.75; P \ 0.0001) [29] .
The present short communication evaluates, in 956 women with ER? disease randomized in IBCSG trials 13-93 and 14-93, the impact of receiving at least 4 years duration of SERM treatment. At each 6-month follow-up visit, SERM start and stop intervals, as well as start and stop dates for interruptions of more than 1 month were recorded by the clinician as reported by the patient. In this report ''SERM adherence'' was defined as the total number of months the patient reported receiving her assigned SERM. A cutoff of 4 years (48 months) was selected because very few patients discontinued their SERM prior to 4 years except due to recurrence. Preliminary analyses (not shown) found no difference in adherence according to the chemotherapy randomization, so results are presented separately by trial and SERM received. Table 1 , giving reasons that endocrine treatment was not begun or was stopped prior to completion, according to SERM group. Forty-two women (4 %) did not begin their endocrine treatment. Nine-hundred-fourteen women (96 %) began assigned SERM therapy, and 305 (32 %) discontinued prior to 48 months of treatment, of whom 106 (35 %) stopped for reason other than recurrence or death unrelated to breast cancer. There was no difference among reasons for stopping early reported for tamoxifen and toremifene. The specific toxicities associated with stopping were not specified in the case report forms. The two groups, those completing 4 or more years of SERM and those stopping early did not differ with regard to the prognostic features of grade, age at diagnosis, tumor size, and number of positive nodes. They also had similar first sites of recurrence, specifically local/regional versus distant metastatic sites.
Results

SERM treatment adherence is provided in
The median follow up for patients included in this evaluation was 9.0 years after enrollment. To avoid the ''guarantee time'' bias (i.e., in order to be adherent with treatment for 4 years a patient must be alive and disease-free for at least 4 years), a ''landmark analysis'' was performed on the cohort of 690 patients known to be alive and disease-free 4 years after study entry [30] . DFS was defined as the length of time from the date of randomization to any relapse (including ipsilateral or contralateral breast recurrence), the appearance 
Patients recurring prior to starting SERM 5 (1) 1 (0.5) 2 (1) 2 (1) 10 (1) Patients not starting SERM 16 (4) 3 (2) 3 (2) 10 (5) 32 (3) Reasons for not starting assigned SERM (18) 47 (24) 45 (23) 199 (21) Patients discontinuing SERM prior to 4 years 43 (12) 17 (9) 19 (10) 27 (14) 106 (11) Reasons for discontinuation Toxicity 21 (6) 9 (5) 13 (7) 14 (7) 57 (6)
Pregnancy desire Pts with \4 years SERM 34 (9) 13 (7) 16 (8) 18 ( (Fig. 1) .
Conclusions
Nonadherence to adjuvant endocrine therapy is increasingly recognized as an important factor influencing the disease outcome of women with early breast cancer. Insufficient adherence and follow-up data are available from most randomised clinical trials to document the prevalence and impact of adherence on DFS: in particular, rates are not always reported in the final published analysis, and reasons for discontinuation, when given, are often not clear. Published data show discontinuation rates generally not exceeding 25 %. Based on data from almost 1,000 women, our studies had a nonadherence rate of 15 % which is comparable to previous observations [2, 10, 14, 19] , with toxicity being the major reason for nonpersistence (54 %). A nonsignificant improved 10-year DFS was observed in patients taking at least 4 years of SERM, which is also consistent with available data in the general population [1, 23] . Our data suggest nonadherence could influence reports of other trial results and subsequent recommendations for everyday clinical practice. As a consequence, consideration of adherence/persistence and routine prospective collection of treatment compliance should be incorporated in clinical trial design and conduct whenever new oral anticancer treatments are being evaluated. In recent years, extended endocrine therapy has been routinely considered for postmenopausal women with ER? breast cancer, particularly among women with node-positive disease [27] , the population evaluated in this report. In addition, the ATLAS [31] and aTTom [32] trials have recently reported a benefit of 10 years of tamoxifen: patients in our trials are, however, not comparable, being all node-positive, requiring chemotherapy, and thus, at higher risk of relapse. To obtain the maximum benefit of their long-lasting oral therapies, women should be more strongly encouraged and supported to complete their assigned treatment, although patients with small(er) risk of recurrence may gain little or only marginal benefit when considering treatment side effects and comorbidities. Strategies for patient education, i.e., increasing patients' understanding of their disease and the appropriate strategies for good patient self-management, should be developed and implemented with the help of health care providers. 
